Shock wave therapy for ED yields short-term benefits

  • Campbell JD & al.
  • Ther Adv Urol
  • 29 Mar 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Low-intensity extracorporeal shock wave therapy (LiESWT) for erectile dysfunction (ED) is well-tolerated with short-term benefits.

Why this matters

  • LiESWT is widely used to treat ED, even though the FDA has not approved it for this purpose.

Study design

  • Researchers analyzed 7 randomized controlled trials assessing LiESWT as a treatment for ED (N=607; mean age, 57-65 years).
  • Funding: Medispec Ltd.

Key results

  • 6 of 7 trials provided data on International Index of Erectile Function-Erectile Function (IIEF-EF) scores at 1 month follow-up; mean difference between treatment and sham was a statistically significant increase in IIEF-EF of 4.23 (95% CI, 0.94-7.53; P=.012).
  • 5 of 7 trials provided data on patients with a baseline erectile hardness score (EHS) ≤2 who improved to EHS ≥3 at 1-month follow-up; pooled relative risk of EHS improvement for treatment vs sham was 6.63 (95% CI, 1.59-27.71; P=.0095).
  • 5 trials reported no adverse events or side effects; 2 reported some patients in both treatment and sham groups experienced local irritation after treatment.

Limitations

  • Long-term results were not available; most trial endpoints were assessed at 1 month after treatment.
  • No trials included intention-to-treat analyses.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit